Abstracts tagged "Psoriatic arthritis"

Abstract Number: 600 • 2017 ACR/ARHP Annual Meeting
Low Rates of Major Adverse Cardiac Events, Malignancies, and Serious Infections in Subjects with Psoriasis and Psoriatic Arthritis Treated with Apremilast for ≥156 Weeks: Pooled Analysis from the Esteem and Palace 1-3 Phase 3 Trials
Arthur Kavanaugh¹, Matthias Augustin², Eric Lespessailles³, Kim A. Papp⁴, Maria Paris⁵, Rongdean Chen⁵, Dafna D Gladman⁶, David M. Pariser⁷ and Ketty Peris⁸, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Institute for Health Care Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ³University of Orleans, Orleans, France, ⁴Probity Medical Research, Waterloo, ON, Canada, ⁵Celgene Corporation, Summit, NJ, ⁶Toronto Western Hospital, Toronto, ON, Canada, ⁷Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, ⁸Catholic University of Rome, Rome, Italy
Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, was effective in phase 3, randomized, placebo (PBO)-controlled trials assessing treatment of moderate to severe plaque psoriasis (ESTEEM…
Abstract Number: 884 • 2017 ACR/ARHP Annual Meeting
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: An Integrated Analysis across Phase 3 and Long-Term Extension Studies
Dafna D Gladman¹, Christina Charles-Schoeman², Iain B. McInnes³, Douglas J. Veale⁴, Bruce Thiers⁵, Daniela Graham⁶, Cunshan Wang⁶, Thomas Jones⁷, Robert Wolk⁶ and Ryan DeMasi⁷, ¹Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of California, Los Angeles, Los Angeles, CA, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴St. Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Medical University of South Carolina, Charleston, SC, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Cardiovascular (CV) disease and cardiometabolic syndrome are common comorbidities/causes of mortality in patients (pts) with psoriatic arthritis (PsA). Tofacitinib is an oral Janus kinase…
Abstract Number: 2554 • 2017 ACR/ARHP Annual Meeting
Disease Activity in Psoriatic Arthritis-ESR Index Maybe a Valid Tool to Evaluate Disease Activity in Patients with Psoriatic Arthritis When CRP Is Not Available
Andrea Lujan Coronel Ale¹, Emilce E Schneeberger¹, Osvaldo Luis Cerda¹, Cecilia Zaffarana¹, Marina Natalia Fornaro², Margarita Landi¹ and Gustavo Citera³, ¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ²Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, buenos aires, Argentina, ³Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: DAPSA is a composite index to assess disease activity in patients with Psoriatic Arthritis (PsA) which includes joint count 66/68, pain and patient´s global…
Abstract Number: 601 • 2017 ACR/ARHP Annual Meeting
Long-Term (4-Year) Efficacy and Safety of Apremilast Monotherapy in DMARD-Naive Subjects with Active Psoriatic Arthritis
Alvin F. Wells¹, Christopher J. Edwards², Alan J. Kivitz³, Paul Bird⁴, Dianne Nguyen⁵, Maria Paris⁵, Lichen Teng⁵ and Jacob A. Aelion⁶, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University Hospital Southampton, Southampton, United Kingdom, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴University Of New South Wales, Sydney, Australia, ⁵Celgene Corporation, Summit, NJ, ⁶West Tennessee Research Institute, Jackson, TN
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune responses that cause joint inflammation and other manifestations of psoriatic arthritis…
Abstract Number: 887 • 2017 ACR/ARHP Annual Meeting
A Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose, Safety, and Pharmacokinetics Study of CC-220 in Subjects with Systemic LUPUS Erythematosus
Richard Furie¹, Victoria P. Werth², Allison Gaudy³, Ying Ye³, Shimon Korish³, Ada Azaryan³, Nikolay Delev³, Douglas Hough³, Michael Weiswasser³, Suktae Choi³ and Peter Schafer³, ¹Northwell Health, Great Neck, NY, ²University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ³Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is a CUL4CRBN E3 ubiquitin ligase modulator that binds to cereblon and leads to potent and deep reduction of the transcription factors Ikaros(IKZF1)…
Abstract Number: 2555 • 2017 ACR/ARHP Annual Meeting
Clinical History of Psoriatic Arthritis over Four Decades
Dafna D Gladman¹, Justine Y. Ye² and Vinod Chandran³, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease associated with psoriasis. Over the past several decades it was recognized that PsA is more common…
Abstract Number: 602 • 2017 ACR/ARHP Annual Meeting
Improvements in Work Productivity with up to 104 Weeks of Apremilast Monotherapy: Results from a Phase 3b, Randomized, Controlled Study in Biologic-NaïVe Subjects with Active Psoriatic Arthritis
Philip J Mease¹, Dafna D Gladman², Eric K Davenport³, Xiaolei Zhou³, Benoit Guerette⁴, Lichen Teng⁴, Satyin Kaura⁴ and Peter Nash⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³RTI Health Solutions, Research Triangle Park, NC, ⁴Celgene Corporation, Summit, NJ, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Patients with active psoriatic arthritis (PsA) may experience disease manifestations across multiple domains, as well as impaired functioning in daily activities at home and…
Abstract Number: 992 • 2017 ACR/ARHP Annual Meeting
The Effect of Anti-TNF Therapy on Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis over One Year – Real Life Data from the Czech Biologics Registry Attra
Jakub Zavada¹, Lenka Szczukova², Karel Pavelka³ and Jiri Vencovsky³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: The ATTRA registry captures more than 95% of patients with RA, PSA or AS treated with biologics in the Czech Republic (CZ). In CZ,…
Abstract Number: 2800 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial
Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Joe Sexton¹, Inge C Olsen³, Nils Bolstad⁴, Merete Lorentzen⁵, Espen A. Haavardsholm⁶, Cato Mork⁷, Jorgen Jahnsen⁸ and Tore K Kvien⁹, ¹Dept Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept of cancer and Molecular medicine, Norwegian University of Science and Technology, Trondheim, Norway, ⁸Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁹Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) , Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 603 • 2017 ACR/ARHP Annual Meeting
Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials
Philip J Mease¹, Dafna D Gladman², Arthur Kavanaugh³, Priscila Nakasato⁴, Benoit Guerette⁴, Lichen Teng⁴ and Peter Nash⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of California, San Diego, School of Medicine, La Jolla, CA, ⁴Celgene Corporation, Summit, NJ, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: The PALACE 1, 2, and 3 trials evaluated the efficacy and safety of apremilast (APR) in subjects with active psoriatic arthritis (PsA) despite prior…
Abstract Number: 997 • 2017 ACR/ARHP Annual Meeting
Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Ana Maria Gheorghiu¹, Alexandru Garaiman², Alexandra Radu², Alina Soare³, Victoria Arama⁴, Dragos Bumbacea⁵, Rucsandra Dobrota⁶, Raida Oneata⁷, Simona Pintilie², Mihaela Milicescu⁷, Ioan Ancuta⁷, Andrei Martin², Mariana Sasu¹, Claudia Ciofu¹, Liviu Macovei¹, Victor Stoica⁷, Mihai Bojinca⁷ and Carina Mihai⁸, ¹Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, CANTACUZINO HOSPITAL, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Infectious Diseases 1 Department, Matei Bals National Institute for Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Department of Pneumology, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁸Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose: Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). Objectives: To assess the incidence of active TB and the efficacy of…
Abstract Number: 604 • 2017 ACR/ARHP Annual Meeting
Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies
Philip J Mease¹, Dafna D Gladman², Juan J. Gomez-Reino³, Stephen Hall⁴, Arthur Kavanaugh⁵, Eric Lespessailles⁶, Georg Schett⁷, Maria Paris⁸, Lichen Teng⁸ and Jürgen Wollenhaupt⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶University of Orleans, Orleans, France, ⁷Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁸Celgene Corporation, Summit, NJ, ⁹Schön Klinik Hamburg-Eilbek, Klinik fur Rheumatologie, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, regulates immune activity in psoriatic arthritis (PsA) patients. We evaluated the long-term safety of APR treatment for…
Abstract Number: 1256 • 2017 ACR/ARHP Annual Meeting
Uptake of Influenza and Pneumococcal Vaccination in Inflammatory Arthritis
Kieran Murray¹ and Douglas J. Veale², ¹Rheumatology, Rheumatology Specialist Registrar, Dublin 4, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose: Inflammatory arthritides such as RA and PsA increase infection risk. The Centre for Disease Control and Prevention (CDC) recommends vaccination against i. influenza for…
Abstract Number: 10L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Dafna D Gladman¹, William Rigby², Valderilio F Azevedo³, Frank Behrens⁴, Ricardo Blanco⁵, Andrzej Kaszuba⁶, Elizabeth Kudlacz⁷, Cunshan Wang⁷, Sujatha Menon⁷, Thijs Hendrikx⁸ and Keith S Kanik⁷, ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ³Federal University of Parana and Edumed Health Research Center and Biotech, Curitiba, Brazil, ⁴Johann Wolfgang Goethe University, Frankfurt, Germany, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁶Specialstyczne Gabinety Lerkarskie "DERMED", Lodz, Poland, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA. In this first study of tofacitinib in patients (pts) with active…
Abstract Number: 90 • 2016 ACR/ARHP Annual Meeting
Impacts of Anti-TNF Treatment on Improvement in Work Place and Household Productivity in Patients with Psoriatic Arthritis
Omer Karadag¹, Ediz Dalkilic², Ahmet Mesut Onat³, Orhan Kucuksahin⁴, Timucin Kasifoglu⁵, Bunyamin Kisacik⁶, Omer Nuri Pamuk⁷, Neslihan Yilmaz⁸, Suleyman Serdar Koca⁹, Veli Yazisiz¹⁰, Pinar Talu Ocakci¹¹, Mehmet Sayarlioglu¹², Ender Terzioglu¹³, Sukran Erten^14,15, Mustafa Ferhat Oksuz¹⁶ and Umut Kalyoncu¹, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department Of Internal Medicine, Division of Rheumatology, Gaziantep University, Gaziantep University,Division of Rheumatology, Gaziantep, Turkey, ⁴Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ⁶Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁷Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ⁸Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ⁹Department of Rheumatology Faculty of Medicine Firat University, Elazig, Turkey, ¹⁰Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹¹Rheumatology, İzmir University Faculty of Medicine, izmir, Turkey, ¹²Rheumatology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey, ¹³Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁴Rheumatology, Ataturk Training and Research Hospital, Ankara, Turkey, ¹⁵Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ¹⁶Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Psoriatic arthritis (PsA) is a unique inflammatory arthritis that affects the skin, nails, and the joints. Most of the patients consider PsA to have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].